Spark Therapeutics Inc. said it would charge $850,000 a patient for a pioneering new treatment for a hereditary form of vision loss—below the $1 million price tag the company had considered, but still a milestone for ever-rising drug prices in the U.S.

To address concerns about the cost of the drug, Luxturna, Spark said it is offering alternative payment arrangements to health insurers, including partial refunds if a patient’s vision doesn’t improve significantly after treatment. The company also is seeking U.S. government...  